Researchers evaluated the efficacy and safety of ixekizumab over a 16-week period for the treatment of juvenile psoriatic arthritis or enthesitis-related arthritis.

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates significant ...

At ObesityWeek 2024, researchers presented the latest data on treatment regimens for chronic weight management, including GLP ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Researchers assessed the safety and efficacy of apremilast over a 48-week period for the treatment of early oligoarticular psoriatic arthritis.

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks.

After peak in 2020, significant decrease seen in firearm injury-related visit rates year over year from 2020 to 2023 ...

The American Academy of Sleep Medicine published guidance regarding the treatment of restless leg syndrome and periodic limb movement disorder.

The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the emergency treatment of known or suspected opioid overdose in adults an ...

The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults.

Researchers found a significant decrease in SBP and DBP in the overall group and in the high-dose group at 6 and 12 months.